Trametinib Causes Reversible Cardiotoxicity in Almost One-Quarter of Exposed Adults With NF1 In the TRAIN trial, 23% of adults with NF1 taking trametinib developed cardiac dysfunction, although it was mostly moderate and reversible.

#Cancer therapy-related cardiac dysfunction (#CTRCD) appeared in 23% of neurofibromatosis type 1 (#NF1) patients receiving #Trametinib monotherapy in the phase 2 TRAIN trial.

Read more: https://bit.ly/4lSnxS2

#RareDisease #MedSky